- Home
- PODC vs UNCY Comparison
PODC vs UNCY Comparison
Compare PODC & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- UNCY
- Stock Information
- Founded
- PODC 2013
- UNCY 2016
- Country
- PODC United States
- UNCY United States
- Employees
- PODC N/A
- UNCY N/A
- Industry
- PODC
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- UNCY Health Care
- Exchange
- PODC Nasdaq
- UNCY Nasdaq
- Market Cap
- PODC 29.7M
- UNCY 31.9M
- IPO Year
- PODC N/A
- UNCY 2021
- Fundamental
- Price
- PODC $1.86
- UNCY $0.53
- Analyst Decision
- PODC Strong Buy
- UNCY Strong Buy
- Analyst Count
- PODC 2
- UNCY 4
- Target Price
- PODC $4.75
- UNCY $5.50
- AVG Volume (30 Days)
- PODC 43.0K
- UNCY 1.9M
- Earning Date
- PODC 11-07-2024
- UNCY 11-13-2024
- Dividend Yield
- PODC N/A
- UNCY N/A
- EPS Growth
- PODC N/A
- UNCY N/A
- EPS
- PODC N/A
- UNCY N/A
- Revenue
- PODC $47,461,000.00
- UNCY N/A
- Revenue This Year
- PODC $33.16
- UNCY N/A
- Revenue Next Year
- PODC $20.37
- UNCY N/A
- P/E Ratio
- PODC N/A
- UNCY N/A
- Revenue Growth
- PODC 23.00
- UNCY N/A
- 52 Week Low
- PODC $1.10
- UNCY $0.20
- 52 Week High
- PODC $2.70
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- PODC 65.89
- UNCY 58.81
- Support Level
- PODC $1.48
- UNCY $0.41
- Resistance Level
- PODC $1.98
- UNCY $0.55
- Average True Range (ATR)
- PODC 0.23
- UNCY 0.06
- MACD
- PODC 0.04
- UNCY -0.00
- Stochastic Oscillator
- PODC 84.42
- UNCY 59.18
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.